(Q39212609)

10 September 2017

title

Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide (English)

1 reference

10 September 2017

0 references

Manthena V S Varma

1

1 reference

10 September 2017

Yurong Lai

2

1 reference

10 September 2017

Emi Kimoto

3

1 reference

10 September 2017

Theunis C Goosen

4

1 reference

10 September 2017

Ayman F El-Kattan

5

1 reference

10 September 2017

Vikas Kumar

6

1 reference

10 September 2017

language of work or name

1 reference

10 January 2013

1 reference

10 September 2017

published in

Pharmaceutical Research

1 reference

10 September 2017

volume

30

1 reference

10 September 2017

issue

4

1 reference

10 September 2017

page(s)

1188-1199

1 reference

Learning from the cerivastatin experience

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

The role of physiologically based pharmacokinetic modeling in regulatory review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Repaglinide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Transporters as a determinant of drug clearance and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Cyclosporine markedly raises the plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Rifampin decreases the plasma concentrations and effects of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Human skeletal muscle drug transporters determine local exposure and toxicity of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

High throughput quantitative assessment of CYP inactivation using 2 concentration points

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0956-5

The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma

21 January 2018

1 reference

12 December 2020

Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake

1 reference

12 December 2020

Studies on the interaction between fibrates and statins using human hepatic microsomes

1 reference

12 December 2020

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination

1 reference

12 December 2020

Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved

1 reference

12 December 2020

Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.

1 reference

12 December 2020

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

1 reference

12 December 2020

Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing

1 reference

12 December 2020

Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport

1 reference

12 December 2020

Pharmacokinetics of repaglinide in subjects with renal impairment

1 reference

12 December 2020

10.1007/S11095-012-0956-5

Identifiers

DOI

1 reference

release_mtovfabxqzgcjih4ndioq337ti

10 September 2017

Fatcat ID

0 references

1 reference